How they work

Semaglutide vs Tirzepatide: How the Two Drugs Actually Differ

Semaglutide hits one receptor, tirzepatide hits two - and in the only head-to-head trial, tirzepatide produced more weight loss, though the two molecules differ in more ways than a single number captures.

Last verified September 14, 2026·14 sources cited·Ozempic Wegovy Mounjaro Zepbound

Semaglutides.org is for information only and is not medical advice. Always talk to a licensed healthcare provider about your own care. Some links to telehealth services are affiliate links, labeled where they appear.

These are two different molecules that do overlapping jobs. They are not two brands of the same thing, and treating them as interchangeable is the single most common mistake people make when comparing them.

Here is what separates them, from the chemistry up to the trial results.

This is an evidence summary, not medical advice. Which medicine suits a particular person, at which dose, is a decision for that person and a healthcare provider.

What are the brand names for each drug?

Start here, because the naming causes most of the confusion.

Molecule	Diabetes brand	Weight-management brand	Maker
Semaglutide	Ozempic (injection), Ozempic tablets, Rybelsus	Wegovy (injection), Wegovy tablets	Novo Nordisk
Tirzepatide	Mounjaro	Zepbound	Eli Lilly

Ozempic and Wegovy contain the same molecule at different doses. Mounjaro and Zepbound contain the same molecule at different doses. Ozempic and Mounjaro contain different molecules. Keeping those two facts straight resolves most arguments.

What is the difference between the molecules?

	Semaglutide	Tirzepatide
Amino acids	31	39
Based on	Human GLP-1	Human GIP
Fatty acid chain	C18 diacid at Lys26	C20 diacid at Lys20
Molecular weight	about 4,114 Da	about 4,814 Da
Receptors activated	GLP-1 receptor	GLP-1 receptor and GIP receptor
DPP-4 protection	Aib at position 8	Aib at positions 2 and 13
Half-life	about 1 week	about 5 days
Dosing	Once weekly (injection); daily (tablet)	Once weekly

Both molecules use the same two survival tricks: a non-standard amino acid where DPP-4 would cut, and a fatty diacid chain that binds albumin so the drug is released slowly and escapes kidney filtration [3][7].

The differences are the backbone and the receptor count. Tirzepatide’s peptide sequence is built on native GIP with engineered cross-reactivity for the GLP-1 receptor, not the other way around [3]. Its longer C20 chain and different attachment point are part of why its half-life lands around five days rather than seven [3].

What does the extra receptor actually do?

GIP - glucose-dependent insulinotropic polypeptide - is the other incretin hormone. Like GLP-1 it boosts insulin when glucose is high. Unlike GLP-1, it does not suppress glucagon.

For years GIP was considered a dead end in type 2 diabetes because it seemed ineffective on its own. Tirzepatide’s clinical results forced a rethink. What is still not settled is why combining the two receptors works better than one.

Two mechanistic explanations are in play, and both are hypotheses rather than established fact:

Imbalanced agonism. Laboratory work describes tirzepatide as an imbalanced dual agonist that engages the GIP receptor more strongly than the GLP-1 receptor [4]. It closely resembles native GIP in how it activates GIPR, but activates the GLP-1 receptor quite differently from native GLP-1 [4].

Biased signaling. At the GLP-1 receptor, tirzepatide favors cyclic AMP production over recruitment of beta-arrestin proteins [4][5]. Beta-arrestin is part of how a cell switches a receptor off and pulls it inside. Less beta-arrestin recruitment means less receptor desensitization, so the signal keeps running longer. Experiments in pancreatic islets found beta-arrestin1 limits the insulin response to GLP-1 but not to tirzepatide [4].

A 2025 review concluded that current evidence does not conclusively classify semaglutide itself as a clinically biased GLP-1 receptor agonist - it engages both pathways meaningfully. So the contrast is real at the bench. Whether it explains the clinical gap is still an open question.

What did the head-to-head trial find?

SURMOUNT-5 is the only randomized head-to-head comparison, published in the New England Journal of Medicine. It enrolled adults with obesity and without diabetes and ran for 72 weeks [1].

The results:

Participants randomized: 751, open-label, maximum tolerated dose of each drug [1]
Weight change at week 72: -20.2% with tirzepatide, -13.7% with semaglutide 2.4 mg - a 6.5-percentage-point difference [1]
Absolute weight loss: 22.8 kg (about 50 lb) versus 15.0 kg (about 33 lb) [2]
Waist circumference: -18.4 cm versus -13.0 cm [1]
Lost at least 25% of body weight (a key secondary endpoint): 31.6% versus 16.1% [13]
Lost at least 30% of body weight (beyond the prespecified key secondary endpoints): 19.7% versus 6.9% [13]

Both drugs had safety profiles consistent with previous experience, with gastrointestinal events the most common adverse effects [1].

That is a clear result, and it is why tirzepatide is usually described as the more effective of the two for weight. But three caveats belong with it.

Caveat one: the semaglutide dose. SURMOUNT-5 used semaglutide 2.4 mg, the highest approved dose at the time. In March 2026 the FDA approved Wegovy HD at 7.2 mg weekly, which produced about 20.7% mean weight loss over 72 weeks in the STEP UP program [9]. The label restricts that dose to adults who have already tolerated 2.4 mg for at least four weeks, so it is an escalation option rather than an alternative starting point [8]. No head-to-head trial has compared 7.2 mg semaglutide with tirzepatide, and comparing numbers across separate trials with different populations is not the same as a randomized comparison.

Caveat two: averages hide individuals. A 6.5-percentage-point difference in group means says nothing about how any specific person will respond. Some people do better on semaglutide. Tolerability often decides more than average efficacy does.

Caveat three: weight is not the only outcome. Each molecule carries its own set of approved indications built on its own outcome trials, and those do not transfer between them.

Do they have different approved uses?

Yes, and this is where the practical decision often gets made.

As of September 2026, semaglutide’s US labeling spans type 2 diabetes glycemic control, cardiovascular risk reduction in established cardiovascular disease, slowing chronic kidney disease progression in type 2 diabetes, chronic weight management in adults and in adolescents 12 and older, and noncirrhotic MASH with moderate to advanced liver fibrosis [6].

Tirzepatide’s labeling covers type 2 diabetes and chronic weight management, with additional indications added on the strength of its own trials.

Indications are earned trial by trial. A benefit demonstrated for one molecule does not carry over to the other, even though they share a receptor.

Do they differ on side effects?

Mostly they overlap. Nausea, vomiting, diarrhea and constipation dominate both, cluster in the first weeks, and are the reason both drugs escalate doses slowly.

Two differences are worth naming.

Dysesthesia at high-dose semaglutide. When the 7.2 mg dose was approved, the label documented altered skin sensations - burning, tingling, skin pain, sensitivity - in 22% of patients on 7.2 mg, compared with 6% on 2.4 mg and 0.3% on placebo [8]. Among 288 patients who experienced it, 2% stopped treatment permanently, 8% interrupted it and 23% reduced the dose; most recovered [8]. This is a dose-related effect, not a semaglutide-versus-tirzepatide effect, but it is new information that did not exist when SURMOUNT-5 was designed.

Oral contraceptives. Semaglutide clinical pharmacology studies found no reduction in oral contraceptive exposure - ethinylestradiol and levonorgestrel exposures were in fact slightly increased - and no dose change is warranted [12]. The Mounjaro label takes the opposite position on tirzepatide: use “may reduce the efficacy of oral hormonal contraceptives,” and it advises patients to switch to a non-oral contraceptive method, or add a barrier method, “for 4 weeks after initiation and for 4 weeks after each dose escalation.” Hormonal contraceptives not given by mouth should not be affected [14]. If contraception matters to you, this is not a detail to gloss over - and it is a question for your prescriber.

Detailed safety comparisons live in our safety coverage.

What about muscle and body composition?

Both drugs cause loss of lean mass along with fat, as substantial weight loss by any method does.

In the STEP 1 semaglutide substudy, 140 participants scanned at 68 weeks lost 15.0% of body weight, 19.3% of fat mass and 9.7% of lean body mass - with lean mass rising as a proportion of total body mass by three percentage points [11]. In the SURMOUNT-1 tirzepatide substudy, the reported split was roughly 60% fat mass and 40% lean mass of total weight lost [10].

Those were separate trials with different designs, populations and scan protocols. They are not a head-to-head comparison of muscle preservation, and anyone presenting them as one is overreaching. DXA lean mass also is not the same thing as skeletal muscle.

Which one should you take?

That is genuinely not a question a website can answer, and any site that gives you a confident answer is selling something.

What the evidence supports saying:

Tirzepatide produced more weight loss than semaglutide 2.4 mg in the one randomized head-to-head trial.
Semaglutide has a broader set of approved indications as of September 2026, including kidney disease and MASH.
Both are given as weekly injections; semaglutide is also available as a daily tablet, tirzepatide is not.
Tolerability, cost, insurance coverage, supply and your other health conditions frequently matter more than the average difference in trial results.

Bring those factors to a healthcare provider. Cost and coverage are covered separately in our access and pricing section, and they change frequently enough that any number printed here would be out of date before you read it.

Sources

Questions people ask

Which is stronger, semaglutide or tirzepatide?

In SURMOUNT-5, the only head-to-head trial, mean weight change at 72 weeks was -20.2% with tirzepatide and -13.7% with semaglutide 2.4 mg. That comparison used semaglutide's approved 2.4 mg dose; a higher 7.2 mg semaglutide dose was approved in March 2026 and has not been compared head to head with tirzepatide.

Is Mounjaro a GLP-1 drug?

Not exactly. Mounjaro contains tirzepatide, which activates both the GLP-1 receptor and the GIP receptor. It is usually grouped with GLP-1 drugs in conversation, but it is a dual agonist and a different molecule from semaglutide.

Are Ozempic and Mounjaro the same thing?

No. Ozempic contains semaglutide; Mounjaro contains tirzepatide. They are different molecules made by different companies with different receptor targets. Wegovy and Zepbound are the weight-management brands of the same two molecules.

Why is tirzepatide more effective for weight loss?

Nobody has proven the reason. Leading hypotheses include the added GIP receptor activity and the way tirzepatide signals at the GLP-1 receptor - favoring cyclic AMP over beta-arrestin recruitment, which means less receptor shutdown over time. Both remain hypotheses.

Do the two drugs have different side effects?

The side effect profiles overlap heavily - gastrointestinal effects dominate both. In SURMOUNT-5 both drugs had safety profiles consistent with prior experience. The high-dose 7.2 mg semaglutide label added dysesthesia, altered skin sensation, which appeared in 22% of patients at that dose.

Can you switch from one to the other?

People do, but the doses are not equivalent and the two molecules are not interchangeable. Any switch is a prescriber decision, and dose selection belongs with a healthcare provider.

Do they interact with birth control differently?

Yes, and this is a real practical difference. Clinical pharmacology studies found semaglutide does not reduce oral contraceptive exposure. The Mounjaro label says tirzepatide may reduce the efficacy of oral hormonal contraceptives and advises switching to a non-oral method, or adding a barrier method, for 4 weeks after starting and for 4 weeks after each dose increase. Contraceptives that are not taken by mouth should not be affected.

Which one is covered by insurance?

Coverage varies by plan, employer, indication and year, and it changes often. That question is answered in our access and pricing coverage rather than here.

This article summarizes FDA labeling, published research and company information current as of September 14, 2026. It is not medical advice and does not replace a conversation with your own healthcare provider. How we research and verify.